~(153)Sm-乙二胺四亚甲基膦酸对 Walker 256癌荷瘤大鼠骨侵袭骨溶解的抑制作用

目的研究１５３Ｓｍ－乙二胺四亚甲基膦酸（１５３Ｓｍ－ＥＤＴＭＰ）对荷瘤大鼠骨侵袭、骨溶解的抑制作用。方法运用Ｘ线骨骼照片和胫骨病理切片，观察Ｗａｌｋｅｒ２５６癌大鼠模型的肿瘤骨侵袭和骨溶解情况。结果荷瘤大鼠静脉注射１５３Ｓｍ－ＥＤＴＭＰ７４，１４８ＭＢｇ／ｋｇ后，遭受Ｗａｌｋｅｒ２５６癌侵袭及发生骨溶解的胫骨数减少近一半，３７ＭＢｇ／ｋｇ组对癌的骨侵袭和骨溶解仍有抑制作用。但各组大鼠的移植瘤重量没有差异。结论１５３Ｓｍ－ＥＤＴＭＰ能抑制Ｗａｌｋｅｒ癌模型大鼠骨侵袭和骨溶解，但对移植瘤生长无抑制作用，故其抗癌骨侵袭、骨溶解的作用不是通过抑制动物移植瘤生长来实现的。     

^153Sm—EDTMP治疗骨骨转移癌的临床观察

目的 评价＾１５３Ｓｍ－乙二胺四亚甲基膦酸（ＥＤＴＭＰ）治疗骨转移癌的临床价值。方法 ４５例临床上确认为恶性肿瘤伴多发性骨转移患者,其中男１６例,女２９例,年龄３１～７６岁,均有显著骨痛。采用两次给药法静脉注射＾１５３Ｓｍ－ＥＤＴＭＰ。结果治疗后骨痛完全缓解者２０例（４４．４％）,骨痛部分缓解者２２例（４８．９％）,无效者３例（６．７％）,止痛总有效率为９３．３％,转移灶缩小或消失总有效率为２６．     

^153Sm—乙二胺四亚甲基磷酸盐治疗骨肿瘤转移性疼痛

本文介绍了一种新的肿瘤转移性疼痛治疗方法－＾１５３Ｓｍ－乙二胺四亚甲基磷酸盐（＾１５３Ｓｍ－ＥＤＴＭＰ）放射药物治疗法。＾１５３Ｓｍ－ＥＤＴＭＰ血液清除快，病变区骨摄取高，对正常组织及造血系统的毒副作用小。经临床近千例验证，＾１５３Ｓｍ－ＥＤＴＭＰ对肿瘤转移性骨痛的缓解率为７６％～９６％，治疗后转移灶完全消失占１０％。＾１５３Ｓｍ－ＥＤＴＭＰ治疗是临床常规治疗无效后缓解及治疗转移性骨痛的首选方法。     

骨膦和^153Sm—EDTMP治疗骨转移癌并发急性白血病1例报告

陈XX，男性，69岁，退休干部，住院号：58820，患者因确诊为乙状结肠癌於93年6月22日在某医院行左半结肠癌根治术。术后病理报告：左半结肠绒毛管状腺癌浸润至肌层，周围淋巴结无转移（0／4），上、下切端阴性。术后恢复良好，术后第28天起采用MOF方案化疗6疗程。94年2月初出现背后痛，呈持续性，逐渐加重，摄X胸椎片（片号：934126）示第9胸椎疑有骨质破坏。ECT骨扫描示第9胸椎转移性病灶（ECT号：0902）。肿瘤相关标志CA－19－9＞300u／ml为强阳性。结合病史诊断为结肠癌骨转移而放94年3月23日收人医院，人院后给予骨吸收抑制剂骨脚…     

^153钐—乙二胺四甲撑膦酸治疗转移性骨癌临床观察

＾１５３Ｓｍ－ＥＤＴＭＰ治疗１３６例转移性骨癌的临床观察结果，显示：病人疼痛缓解总有效率为９０．４％。小剂量连续重复治疗不仅具有良好的镇痛效果，还能提高病人生活质量，且有一定的缓解骨转移作用，无严重的毒副反应。     

帕米膦酸二钠和^153Sm—EDTMP治疗骨继发性恶性肿瘤疗效对比 …

帕米膦酸二钠（ＡＰＤ）与＾１５３钐－乙二胺四甲基膦酸（１５３Ｓｍ－ＥＤＴＭＰ）皆为治疗骨继发性恶性肿瘤的较新药物，为比较两者的治疗效果，将４２例骨继发性患者随机分为ＡＰＤ组和＾１５３Ｓｍ－ＥＤＴＭＰ组每组各２１例，结果显示：ＡＰＤ和＾１５３Ｓｍ－ＥＤＴＭＰ组对患者骨痛缓解率分别为７６．１９％，９０．４８％（Ｐ〉０．０５），ＡＰＤ与＾１５３Ｓｍ－ＥＤＴＭＰ对骨转移灶控制率分别为４７．６２％，２３．８     

^153Sm—EDTMP内照射配合外照射治疗多发性骨转移瘤

由于恶性肿瘤诊断及治疗水平不断进步,使其疗效有了提高,患者生存期相应延长,骨转移机会相应增多。我们对３０例多发性骨转移瘤患者采用１５３Ｓｍ－ＥＤＴＭＰ内照射配合外照射治疗,止痛总有效率高于对照组,现初步总结如下。１材料与方法１．１病例资料我院从１９９...     

^153Sm—EDTMP治疗肿瘤骨转移止痛效果相关因素分析

目的 分析影响＾１５３Ｓｍ－ＥＤＴＭＰ对肿瘤转移性骨痛治疗效果的相关因素，方法 对我院近两年使用＾１５３Ｓｍ－ＥＤＴＭＰ行内照射治疗的５９例肿瘤转移性骨病人进行回顾性分析，按年龄，病灶数量，不同肿瘤分组，单次剂量给予＾１５３Ｓｍ－ＥＤＴＭＰ１８．５－３７ＭＢｑ／ｋｇ静脉注射，第２天行全身骨显像现查放射分布情况，建立随访。结果 总有效率为９３．６％，在年龄组中，以老年组效果最好，止痛有效率为９６．９     

^153Sm—EDTMP治疗骨转移性疼痛89例疗效观察

恶性肿瘤骨转移所致疼痛是影响晚期肿瘤患者生活质量的重要原因。我们使用153Sm-EDTMP治疗骨转移疼痛患者89例,现报告如下。1　资料与方法收集1997年1月—1998年12月间治疗的多发性骨转移患者89例,其中肺癌30例,乳腺癌22例,鼻咽癌8例,前列腺癌7例,结直肠癌8例,食管癌4例,...     

A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate

A phase II study of ¹⁵³Sm ethylenediaminetetramethylene phosphonate (¹⁵³Sm-EDTMP) palliative treatment was conducted on 23 patients with painful disseminated skeletal metastases. The administered activity of ¹⁵³Sm-EDTMP was determined by prospective dosimetry and the radiation absorbed dose to bone marrow was fixed at 2 Gy. Symptomatic relief of bone pain was experienced by 14 of 23 evaluable patients (61%) with a median duration of 8 weeks (range 0–40). Toxicity was limited to myelosuppression with median nadir counts of leucocytes 3.3 × 10⁹/l (range 1.0–7.5) and platelets 133 × 10⁹/l (range 24–176) occurring at 2 weeks and 4 weeks, respectively. Retreatment with ¹⁵³Sm-EDTMP was studied in 15 patients, including in 4 of the 23 patients treated with a single dose. The retreatment median radiation absorbed dose to red marrow was 1.9 Gy given at a median of 9 weeks (range 6–38) after initial treatment. Good control of pain was obtained in 13 of these patients (87%). Both the median duration of pain control (24 weeks) and survival (9 months) in the retreated group were substantially greater than for patients treated with a single dose, where duration was 8 weeks and survival 4 months. Additional toxicity in the retreated patients was confined to anaemia which required blood transfusion in 9 of the 15 patients (60%).     

Hormones of the pituitary-adrenal axis in rats bearing the Walker 256 carcinoma

Male Sprague-Dawley rats (125-150 g) were implanted intramuscularly with the Walker 256 carcinoma. After 3, 5 or 7 days, tumor-bearing rats, along with controls, were killed and plasma levels of adrenocorticotropic hormone (ACTH), beta-endorphin and corticosterone were assessed. Plasma levels of all 3 hormones declined with time following tumor implantation. Plasma levels of ACTH and corticosterone were statistically significantly less than plasma levels of these same hormones in control rats by 7 days post-implantation. Levels of these hormones were reduced by 42% and 33%, respectively, relative to control levels by 7 days. beta-Endorphin levels declined much more rapidly following tumor implantation than did either of the other 2 hormones. beta-Endorphin was significantly decreased by 3 days post-implantation and by 7 days the plasma levels of this factor were 83% lower than in control rats.     

Role of pinealectomy on Walker 256 carcinoma in rats

After years of investigation, today it is generally agreed that mammalian pineal is a functioning organ with endocrine-like properties. Several investigators in the past have shown that pinealectomy possibly alters the growth and spread of tumors in rodents. An experimental system has been devised in this laboratory to study the effects of pinealectomy on the growth and spread of Walker 256 carcinoma in rats. One hundred and ten inbred Holtzman male rats weighing 40–60 g were used. Thirty-nine rats were pinealectomized. Thirty-five rats were subjected to a comparative trauma and bleeding but the pineal was left intact (sham-operated). Thirty-six rats served as controls. Five weeks after operation all the rats were inoculated with 500,000 tumor cells. The rats were observed for 23 days after tumor inoculation. Autopsies were performed on the twenty-fourth day. Results showed the tumor volumes were 149.37 ± 26.46 ml in pinealectomized rats, 104.79 ± 19.97 ml in the sham-operated group, and 103.59 ± 19.61 ml in the control group. This was statistically significant (p = 0.01). Metastatic tumor involvement of the mediastinal lymph nodes occurred in 82% of the pinealectomized rats versus 38% of the controls and 46% of sham-operated animals. Metastatic tumor involvement occurred in 79% of the lungs in pinealectomized rats versus 31% in the sham-operated and 36% in the control animals.     

Morphologic aspect of the placenta in young and adult pregnant rats bearing Walker 256 carcinoma

In the present study we investigated the influence of Walker 256 tumor growth on the modification of placental morphology and on fetal development in young and adult pregnant rats. After mating, female rats were divided into six groups: young control pregnant (Y), young pregnant with tumor (Yw), young pregnant injected with ascitic fluid (Ya), adult control pregnant (A), adult pregnant with tumor (Aw), and adult pregnant injected with ascitic fluid (Aa). Rats from tumor-bearing groups (Yw and Aw) were injected with 2.5 x 10(6) viable tumor cells into the right flank. Rats from Ya and Aa groups received daily inoculations of ascitic fluid (2.0 ml, i.p.) obtained from tumor-bearing rats without tumor cells. After 21 days, all animals were killed and the placentas were weighed and fixed with paraformaldehyde for histological analysis. Compared with control groups (Y and A), both tumor-bearing groups (Yw and Aw) presented the following changes: i) hemorrhage in the decidua and in the trophoblast giant cell layer; ii) disarrangement of the spongy zone, iii) restricted delimitation of the maternal and fetal blood vessels in the placental labyrinth; iv) hemorrhage and edema in the placental labyrinth. Similar results were observed in the placenta of groups injected with ascitic fluid (Ya and Aa). These results indicate that tumor development during pregnancy can have deleterious effects on placenta and fetus. These observations extend our previous data of extensive fetal reabsorption in both pregnant tumor-bearing and ascitic fluid-injected animals. These changes in placental morphology may be related to the synthesis and release of some factors by the tumor and the host cells, which could act directly or indirectly on placental tissue.